Your browser doesn't support javascript.
loading
IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation.
Xu, Yipeng; Pachnikova, Gabriela; Wang, He; Wu, Yaoyao; Przybilla, Dorothea; Schäfer, Reinhold; Chen, Zihao; Zhu, Shaoxing; Keilholz, Ulrich.
Afiliação
  • Xu Y; Department of Urology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou, China; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences,
  • Pachnikova G; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Wang H; The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Wu Y; The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Przybilla D; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Schäfer R; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
  • Chen Z; Department of Urology, Southern Medical University, Guangzhou, China.
  • Zhu S; Department of Urology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou, China; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences,
  • Keilholz U; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany.
Bosn J Basic Med Sci ; 22(4): 580-592, 2022 Jul 29.
Article em En | MEDLINE | ID: mdl-35694767
Preclinical models of tumors have the potential to become valuable tools for commercial drug research and development, and 3D culture systems are gaining traction in this area, particularly in prostate cancer (PCa) research. However, nearly all 3D drug design and screening assessments are based on 2D experiments, suggesting limitations of 3D drug testing. To simulate the natural response of human cells to the drug, we detected the half-maximal inhibitory concentration (IC50) changes of 2D/3D LNCaP cells in the drug docetaxel, as well as the sensitivity of different morphologies of 2D/3D LNCaP to docetaxel treatment. In contrast to 2D LNCaP cells, the evaluation of LNCaP spheroids' susceptibility to treatment was more complicated; the fitness of IC50 curves of 2D and 3D tumor cell preclinical models differs significantly. IC50 curves were unsuitable for large-sized LNCaP spheroids. More evaluation indexes (such as max inhibition) and experiments (such as spheroids formation) should be explored and performed to evaluate the susceptibility systematically.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antineoplásicos Tipo de estudo: Diagnostic_studies Limite: Humans / Male Idioma: En Revista: Bosn J Basic Med Sci Assunto da revista: MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de publicação: Bósnia-Herzegóvina

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antineoplásicos Tipo de estudo: Diagnostic_studies Limite: Humans / Male Idioma: En Revista: Bosn J Basic Med Sci Assunto da revista: MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de publicação: Bósnia-Herzegóvina